Position in ABBV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$9,207,759
+$2,416,634 QoQ
Shares Held
36,591
+17.2% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.31%
of 13F equity value
Holder Rank
#967
of 4,153 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Hamilton Capital Partners Inc. holds $142,110,591 across 8 Drug Manufacturers - General names. ABBV ranks #3 (6.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
43,560 | $52,247,175 | |
| 2 | JNJ |
Johnson & Johnson
|
172,604 | $43,836,237 | |
| 3 | ABBV |
AbbVie Inc.
This page
|
36,591 | $9,207,759 | |
| 4 | MRK |
Merck & Co., Inc.
|
62,293 | $8,004,650 | |
| 5 | AMGN |
Amgen Inc
|
21,267 | $7,701,206 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
130,247 | $7,504,832 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
54,572 | $6,894,626 | |
| 8 | PFE |
Pfizer Inc
|
278,825 | $6,714,106 |
All Filings in ABBV
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,207,759 | 36,591 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $6,791,125 | 31,225 | Shares | Sole | 2026-08-14 | |
| 2025-12-31 | $5,576,755 | 24,407 | Shares | Sole | 2026-08-14 | |
| 2025-09-30 | $4,894,755 | 21,140 | Shares | Sole | 2026-08-14 | |
| 2025-06-30 | $4,521,331 | 24,358 | Shares | Sole | 2026-08-14 | |
| 2025-03-31 | $4,081,659 | 19,481 | Shares | Sole | 2026-08-14 | |
| 2024-12-31 | $3,564,662 | 20,060 | Shares | Sole | 2026-08-14 | |
| 2024-09-30 | $4,458,308 | 22,576 | Shares | Sole | 2026-08-14 | |
| 2024-06-30 | $4,535,846 | 26,445 | Shares | Sole | 2026-08-14 | |
| 2024-03-31 | $4,545,033 | 24,959 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||